<img src="https://ml.globenewswire.com/Resource/Download/e9457092-692d-4bfd-b361-9799ee8d73cd?size=2" nborder="0" align="left" hspace="5" vspace="5" title="LOGO KNIGHT 256X256px.jpg" alt="Knight Therapeutics"/>MONTREAL, May 12, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:  GUD) ("Knight"), a pan-American (ex-USA) pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026 at 9:00 am ET at the InterContinental New York Barclay hotel in New York City. About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at <a href="https://www.globenewswire.com/Tracker?data=aicca8FR7FGmgM5Z7mOYMsUGwRL4it32T5OtgPmnpq9L_dUJDVtLhKwYUbWy01NUocSMoP-ir5UwK-AVGxkJNw==" rel="nofollow" target="_blank" title="www.knighttx.com">www.knighttx.com</a> or <a href="https://www.globenewswire.com/Tracker?data=3Mx7gK9u81DfkdD76EnJneeGgkqKDznLivEIDaK7c-mMqONY37VDS5_UNmWuFqn3PHTvwCY5KNGZbJjk569CBhAgvVw2zDyw-go-YOoDfxs=" rel="nofollow" target="_blank" title="www.sedarplus.ca">www.sedarplus.ca</a>. Forward-Looking Statement This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2025, as filed on <a href="https://www.globenewswire.com/Tracker?data=3Mx7gK9u81DfkdD76EnJnXXKUHLOuYQn782zYKHejQwf6PUHMHaX8X6EmvkBQGuuB4PnTrhFbGKI_seJhq3AhKb45F33044whQTYjsjoXYk=" rel="nofollow" target="_blank" title="www.sedarplus.ca">www.sedarplus.ca</a>. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law. CONTACT INFORMATION: <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="max-width:50%; width:50%; min-width:50%;;vertical-align: top ; ">Investor Contact:</td><td style="max-width:50%; width:50%; min-width:50%;;vertical-align: top ; "> </td></tr><tr><td style="vertical-align: top ; ">Knight Therapeutics Inc.</td><td style="vertical-align: top ; "> </td></tr><tr><td style="vertical-align: top ; ">Samira Sakhia</td><td style="vertical-align: top ; ">Arvind Utchanah</td></tr><tr><td style="vertical-align: top ; ">President &amp; Chief Executive Officer</td><td style="vertical-align: top ; ">Chief Financial Officer</td></tr><tr><td style="vertical-align: top ; ">T: 514.484.4483</td><td style="vertical-align: top ; ">T. +598.2626.2344</td></tr><tr><td style="vertical-align: top ; ">F: 514.481.4116</td><td style="vertical-align: top ; "> </td></tr><tr><td style="vertical-align: top ; ">Email: <a href="mailto:IR@knighttx.com" rel="nofollow" target="_blank" title="IR@knighttx.com">IR@knighttx.com</a></td><td style="vertical-align: top ; ">Email: <a href="mailto:IR@knighttx.com" rel="nofollow" target="_blank" title="IR@knighttx.com">IR@knighttx.com</a></td></tr><tr><td style="vertical-align: top ; ">Website: <a href="https://www.globenewswire.com/Tracker?data=kfD_m-QtEFrI4JaPYOBqNJk4osV9-a-eG_pa_5BpTQcVHONTsJDnYm5HNRx99maYLsDK1rpSYNlMkiyyO4YL_Q==" rel="nofollow" target="_blank" title="www.knighttx.com">www.knighttx.com</a></td><td style="vertical-align: top ; ">Website: <a href="https://www.globenewswire.com/Tracker?data=kfD_m-QtEFrI4JaPYOBqNECgfpinr-OYcHyvRMlS3rYOrvRf-vJssjcK6hWhRZrv81lwF4pDh4E98NVDMJd4Wg==" rel="nofollow" target="_blank" title="www.knighttx.com">www.knighttx.com</a></td></tr></table> <img alt="" src='https://ml.globenewswire.com/media/OGQwNDRlY2QtZmExMC00YzI3LTg0YzgtZmFkOTMxNmFkM2Y0LTEwOTg0ODItMjAyNi0wNS0xMi1lbg==/tiny/Knight-Therapeutics.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Knight to Present at the 2026 RBC Capital Markets Global Healthcare Conference in New York City

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn